Drug Approval | May 08, 2024
USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
Improvements were also seen in complete response rates, duration of response, and time to next treatment
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Subscribe To Our Newsletter & Stay Updated
